Towards immunotherapeutic drugs and vaccines against multiple sclerosis
Maria Katsara,
John Matsoukas,
George Deraos,
Vasso Apostolopoulos,
Maria Katsara
Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, Victoria 3084, Australia
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorJohn Matsoukas
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorGeorge Deraos
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorCorresponding Author
Vasso Apostolopoulos
Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, Victoria 3084, Australia
*Corresponding author: Tel, 613-92870666; Fax, 613-92870600; E-mail, [email protected]Search for more papers by this authorMaria Katsara,
John Matsoukas,
George Deraos,
Vasso Apostolopoulos,
Maria Katsara
Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, Victoria 3084, Australia
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorJohn Matsoukas
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorGeorge Deraos
Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece
Search for more papers by this authorCorresponding Author
Vasso Apostolopoulos
Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, Victoria 3084, Australia
*Corresponding author: Tel, 613-92870666; Fax, 613-92870600; E-mail, [email protected]Search for more papers by this authorThis work was supported by grants from the Ministry of Development Secretariat of Research and Technology of Greece (Grant Aus. 005) and Du Pré grant from the Multiple Sclerosis International Federation to MK, and a National Health and Medical Research Council of Australia R. Douglas Wright Fellowship (223316) to VA
Abstract
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Numerous treatment options are available to MS patients; however, these options need to be improved. Herein, we review the current drugs and therapeutic approaches available to MS patients, preclinical trial interventions and recent animal model studies for the potential therapy of MS. Since the current treatment of MS remains elusive and is limited, animal studies and clinical research offers an optimistic outlook.
References
- 1 Thompson A, Battaglia M, Douglas I, Porter B, Rampani P, Dua T, Prilipko L et al. WHO Atlas of MS. 2006: September.
- 2 Visiongain Multiple Sclerosis Market Analysis and Forecasts Report 2007–2022. 2007: August.
- 3 Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85: 299–302.
- 4 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46: 907–911.
- 5 Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon β-1b for multiple sclerosis: report of a consensus conference. Neurology 1996, 46: 12–18.
- 6 Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4: 647–653.
- 7 Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Pia Amato M. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2007, 266: 25–30.
- 8 Kappos L, Stolle U, Wilhelm U. Occurrence of cancer after long-term treatment with azathioprine in MS and myasthenia gravis. Ann Report, Max Planc Soc Clin Res Unit for MS 1985, 3: 13–17.
- 9 Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005, 252 Suppl 3: iii44–iii50.
- 10 Hartung HP, Kieseier BC, Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J Neurol 2005, 252 Suppl 5: v30–37.
- 11 Kappos L, Hartung HP. 10 years of interferon β-1b (Betaferon®) therapy. J Neurol 2005, 252 Suppl 3: iii1–iii2.
- 12
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data.
Mult Scler
2001, 7: 179–183.
10.1177/135245850100700308 Google Scholar
- 13 Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB et al. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002, 51: 481–490.
- 14 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39: 285–294.
- 15 Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999, 53: 139–148.
- 16 Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006, 28: 461–474.
- 17 Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985, 3: 123–132.
- 18 Noseworthy JH, Ebers GC, Roberts R. Cyclophosphamide and MS. Neurology 1994, 44: 579–581.
- 19 Shefner JM, Mackin GA, Dawson DM. Lower motor neuron dysfunction in patients with multiple sclerosis. Muscle Nerve 1992, 15: 1265–1270.
- 20 Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 64: 1336–1342.
- 21 Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899–910.
- 22 Tysabri: Annex I - Summary of product characteristics. European Medicines Agency 2008: March.
- 23 Natalizumab: a new drug. Multiple Sclerosis: risky market approval. Prescrire Int 2008, 17: 7–10.
- 24 Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007, 68: 1299–1304.
- 25 Rudick RA, Cutter G. Interferon-β for multiple sclerosis: Long-term benefits? Ann Neurol 2007, 61: 283–285.
- 26 Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007, 62: 335–346.
- 27 Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007, 6: 431–441.
- 28 Miller D. Multiple sclerosis: new insights and therapeutic progress. Lancet Neurol 2007, 6: 5–6.
- 29 Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007, 6: 903–912.
- 30 Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007, 68: 1390–1401.
- 31 Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001, 56: 702–708.
- 32 Yong VW. Differential mechanisms of action of interferon-β and glatiramer aetate in MS. Neurology 2002, 59: 802–808.
- 33 Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells—specificity and promiscuity. Proc Natl Acad Sci USA 1994, 91: 4872–4876.
- 34 Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 1999, 96: 634–639.
- 35 Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000, 105: 967–976.
- 36 Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000, 97: 7452–7457.
- 37 Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003, 24: 131–138.
- 38 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45: 1268–1276.
- 39 Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007, 64: 1407–1415.
- 40 Crowe PD, Qin Y, Conlon PJ, Antel JP. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000, 48: 758–765.
- 41 Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000, 6: 1176–1182.
- 42 Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002, 104: 105–114.
- 43 Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6: 1167–1175.
- 44 Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, Kavanagh D et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996, 2: 1109–1115.
- 45 Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, Smith L et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analy sis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV β 6 CDR2 peptide. J Neuroimmunol 1997, 76: 29–38.
- 46 Bourdette DN, Chou YK, Whitham RH, Buckner J, Kwon HJ, Nepom GT, Buenafe A et al. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. J Immunol 1998, 161: 1034–1044.
- 47 Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, LaTocha D, Yadav V et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008, 123: 66–78.
- 48 Tselios T, Daliani I, Deraos S, Thymianou S, Matsoukas E, Troganis A, Gerothanassis I et al. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. Bioorg Medicinal Chemi Lett 2000, 10: 2713–2717.
- 49 Tselios T, Daliani I, Probert L, Deraos S, Matsoukas E, Roy S, Pires J et al. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP87-99 analogue and effects of cyclic peptides. Bioorg Med Chem 2000, 8: 1903–1909.
- 50 Tselios T, Probert L, Daliani I, Matsoukas E, Troganis A, Gerothanassis IP, Mavromoustakos T et al. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J Med Chem 1999, 42: 1170–1177.
- 51 Tselios T, Apostolopoulos V, Daliani I, Deraos S, Grdadolnik S, Mavromoustakos T, Melachrinou M et al. Antagonistic effects of human cyclic MBP87-99 altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J Med Chem 2002, 45: 275–283.
- 52 Matsoukas J, Apostolopoulos V, Kalbacher H, Papini AM, Tselios T, Chatzantoni K, Biagioli T et al. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem 2005, 48: 1470–1480.
- 53 Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. A double mutation of MBP83-99 peptide induces IL-4 responses and antagonizes IFN-γ responses. J Neuroimmunol 2008 (in press).
- 54 Tselios TV, Lamari FN, Karathanasopoulou I, Katsara M, Apostolopoulos V, Pietersz GA, Matsoukas JM et al. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal Biochem 2005, 347: 121–128.
- 55 Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006, 118: 372–383.
- 56 Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000, 18: 3174–3184.
- 57 Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr Mol Med 2001, 1: 469–474.
- 58 Apostolopoulos V, McKenzie IF, Pietersz GA. Generation of MUC1 cytotoxic T-cells in mice and epitope mapping. Methods Mol Biol 2000, 125: 455–462.
- 59
Apostolopoulos V,
Pietersz GA,
Gordon S,
Martinez-Pomares L,
McKenzie IF.
Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.
Eur J Immunol
2000, 30: 1714–1723.
10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 60 Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995, 92: 10128–10132.
- 61 Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996, 14: 930–938.
- 62 Apostolopoulos V, Xing PX, McKenzie IF. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res 1994, 54: 5186–5193.
- 63 Apostolopoulos V, Yu M, Corper AL, Teyton L, Pietersz GA, McKenzie IF, Wilson IA et al. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol 2002, 318: 1293–1305.
- 64 Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, Plebanski M et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003, 100: 15029–15034.
- 65 Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 1997, 15: 1586–1593.
- 66 Katsara M, Yuriev E, Ramsland PR, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2. Mol Immunol 2008 (in press).
- 67 Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, Matsoukas J et al. Round and round we go: cyclic peptides in disease. Curr Med Chem 2006, 13: 2221–2232.
- 68 Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 modulate immune responses in SJL/J mice. J Med Chem 2008 (in press).
